News | June 26, 2021
Shilpa Medicare receives DRDO approval for 2DG manufacturing
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
The company has predominantly built a portfolio into veterinary products
The end user can validate the authenticity of the product by scanning the digital code with the help of a smartphone letting the end user know it is safe to use
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
